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S U M M A R Y
Background: Leprosy is an infectious disease caused by Mycobacterium leprae that affects the skin and
nerves. Although curable with multidrug therapy, leprosy is complicated by acute inﬂammatory
episodes called reactions, which are the major causes of irreversible neuropathy in leprosy that occur
before, during, and even after treatment. Early diagnosis and prompt treatment of reactions reduces the
risk of permanent disability.
Methods: This exploratory study investigated whether urinary metabolic proﬁles could be identiﬁed
that correlate with early signs of reversal reactions (RR). A prospective cohort of leprosy patients with
and without reactions and endemic controls was recruited in Nepal. Urine-derived metabolic proﬁles
were measured longitudinally. Thus, a conventional area of biomarker identiﬁcation for leprosy was
extended to non-invasive urine testing.
Results: It was found that the urinary metabolome could be used to discriminate endemic controls from
untreated patients with mycobacterial disease. Moreover, metabolic signatures in the urine of patients
developing RR were clearly different before RR onset compared to those at RR diagnosis.
Conclusions: This study indicates that urinary metabolic proﬁles are promising host biomarkers for the
detection of intra-individual changes during acute inﬂammation in leprosy and could contribute to early
treatment and prevention of tissue damage.
 2016 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
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jou r nal h o mep ag e: w ww .e lsev ier . co m / loc ate / i j id1. Introduction
Leprosy is a complex infectious disease often resulting in
severe, life-long disabilities.1 It presents in different clinicopatho-
logical forms2,3 and is considered a major threat in developing
countries by the World Health Organization (WHO), remaining
endemic in Africa, South America, and Asia. Every year approxi-
mately 220 000 new patients are still diagnosed, and this
incidence rate has been essentially stable over the last decade.
Furthermore, with increasing migration, new cases are also being
detected in developed countries, where initial misdiagnosis is
likely to occur.4–6
Although leprosy can be treated effectively with multidrug
therapy (MDT), it is complicated by acute inﬂammatory episodes* Corresponding author. Tel.: +31-71-526-1974; fax: +31-71-526-6758.
E-mail address: a.geluk@lumc.nl (A. Geluk).
http://dx.doi.org/10.1016/j.ijid.2016.02.012
1201-9712/ 2016 The Authors. Published by Elsevier Ltd on behalf of International So
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).called leprosy reactions. These immunological complications,
occurring before, during, and after treatment in 30–50% of the
patients, represent the major cause of leprosy-related neurological
damage.7,8 Two types of reaction are recognized: reversal reactions
(RR) or type 1 reactions and erythema nodosum leprosum (ENL) or
type 2 reactions. RRs, which affect 30% of leprosy patients at least
once,9 coincide with characteristic CD4+ T-cell inﬁltrations of skin
and nerve lesions.10,11 Prompt diagnosis and treatment aids
recovery signiﬁcantly, thereby reducing the risk of permanent
disability.12,13 Unfortunately, reactions are frequently misdiag-
nosed due to decreased expertise within integrated health
services.9 Therefore, sensitive tests based on dependable biomark-
ers for early diagnosis of reactions are urgently needed.
Since leprosy endemic areas are often lacking in sophisticated
laboratories, it is imperative to develop diagnostic tests that are
suitable for the ﬁeld setting. Similarly, home-monitoring of chronic
diseases with inﬂammatory episodes requires ease in test
performance. Besides the selection of suitable biomarkers, anciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
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no Rxn t = 0 0.050 TT/BT
no Rxn t = 0 0.045 TT/BT
no Rxn t = 0 2.919 BL/LL
no Rxn t = end 1.325 BL/LL
no Rxn t = 0 0.078 TT/BT
no Rxn t = 0 0.636 TT/BT
no Rxn t = 0 3.146 BL/LL
no Rxn t = 0 0.009 TT/BT
no Rxn t = 0 0.203 TT/BT
no Rxn t = end 0.057 TT/BT
no Rxn t = 0 0.020 TT/BT
no Rxn t = 0 3.147 BL/LL
no Rxn t = 0 1.349 BL/LL
no Rxn t = 0 1.700 BL/LL
no Rxn t = 0 0.055 TT/BT
no Rxn t = 0 0.032 TT/BT
no Rxn t = 0 0.225 TT/BT
no Rxn t = 0 2.550 BL/LL
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samples. Using urine samples rather than venous blood will avoid
the need for a trained phlebotomist, reduce costs, and improve
ease of use. However, host-derived biomarkers for mycobacterial
diseases based on urine have not yet been reported.
The rapidly evolving ﬁeld of metabolomics provides a
technological basis for the comprehensive analysis of urinary
metabolites and the discovery of disease-associated biomarkers in
urine. The feasibility of the approach has already been established
in clinical studies.14,15 Indeed, it has been shown that the
metabolic composition of urine reﬂects the physiological status
of an organism and as such can be a useful readout of multiple
(patho)physiological processes.14–16
To investigate whether disease-speciﬁc metabolites could be
detected in urine, as a non-invasive body ﬂuid, and to identify
associations between such urinary metabolites and the occurrence
of leprosy reactions, an exploratory metabolomics analysis was
performed in leprosy patients in Nepal.
2. Materials and methods
2.1. Study participants
Recruitment took place in Nepal (Mycobacterial Research
Laboratories, Kathmandu).17 Leprosy prevalence was 1.1–0.79/
10 000, new case detection rate (NCDR) 1.67– 1.15/10 000 (Annual
Report 2012–2013, Leprosy Control Division, Department of Health
Services, Kathmandu). Patients and healthy individuals from the
same area (endemic controls) were recruited on a voluntary basis
between February 2008 and March 2013 (Tables 1 and 2). Leprosy
was diagnosed based on clinical, bacteriological, and histological
observations and classiﬁed by skin biopsy according to Ridley and
Jopling.1 Clinical monitoring for reactions was performed during
monthly clinic visits. Clinical and demographic data were collected
in databases with a special emphasis on standardizing data
collection and the deﬁnition of reactions between the cohorts. For
patients who presented with a reaction, the type, severity, skin and/
or nerve involvement, number of lesions, and relapse were noted in
accordance with state-of-the-art clinical expertise and international
consensus scoring.18 Endemic controls were assessed for the
absence of clinical signs and symptoms of leprosy and tuberculosis
(TB). Staff of leprosy and TB clinics were excluded.
2.2. Ethics
This study was performed in accordance with the Declaration of
Helsinki (2008 revision). Participants were informed about theTable 1
Study cohort in Nepala
Categoryb Number Leprosy type
EC 34 -
No Rxn t = 0 28 16 TT/BT 12 BL/LL
No Rxn t = end 11 4 TT/BT 7 BL/LL
RR t = 0 7 3 BT 4 BL/LL
RR t = x 24 12 BT 12 BL/LL
RR t = end 19 8 BT 11 BL/LL
Total 123
TT, tuberculoid; BT, borderline tuberculoid; BL, borderline lepromatous; LL,
lepromatous.
a Newly diagnosed leprosy patients without reactions (no Rxn) were sampled
before (t = 0) and after treatment (t = end); leprosy patients developing reactions
during the study were sampled in the absence of any clinical signs of reactions and
at least 3 months before RR (t = 0), at RR diagnosis before steroids (t = x), or after
multidrug therapy and RR at least 1 month after the end of steroids (t = end).
b EC, endemic control; Rxn, reaction; RR, reversal reaction.
no Rxn t = end 1.309 BL/LL
no Rxn t = 0 0.305 TT/BT
no Rxn t = end 0.190 TT/BT
no Rxn t = 0 0.199 TT/BT
no Rxn t = end 0.118 TT/BT
no Rxn t = 0 0.010 TT/BT
no Rxn t = 0 2.565 BL/LL
no Rxn t = end 0.304 BL/LL
no Rxn t = 0 0.193 BL/LL
no Rxn t = 0 3.012 BL/LL
no Rxn t = end 2.025 BL/LL
no Rxn t = 0 1.229 BL/LL
no Rxn t = end 0.020 BL/LL
no Rxn t = 0 0.117 TT/BT
no Rxn t = end 0.034 TT/BT
no Rxn t = 0 0.803 BL/LL
no Rxn t = end 0.315 BL/LL
no Rxn t = 0 1.161 BL/LL
no Rxn t = end nt BL/LL
no Rxn t = 0 0.159 TT/BT
no Rxn t = 0 0.171 TT/BT
PGL-I (OD) classiﬁcation
RR during study t = 0 0.133 TT/BT
RR during study t = x nt TT/BT
RR during study t=0 1.764 BL/LL
RR during study t=x 2.072 BL/LL
RR during study t=end 0.095 BL/LL
RR during study t = 0 0.143 TT/BT
RR during study t = x 0.259 TT/BT
RR during study t = end 1.391 TT/BT
RR during study t = 0 0.866 BL/LL
RR during study t = x 2.814 BL/LL
RR during study t = end 0.098 BL/LL
RR during study t = 0 0.139 TT/BT
RR during study t = x 3.398 TT/BT
RR during study t = 0 0.307 BL/LL
RR during study t = 0 0.214 BL/LL
RR at recruitment t = x 1.619 BL/LL
RR at recruitment t = end 0.747 BL/LL
RR at recruitment t = x 2.205 BL/LL
RR at recruitment t = end 0.208 BL/LL
RR at recruitment t = x 0.017 TT/BT
RR at recruitment t = end 0.021 TT/BT
RR at recruitment t = x 0.786 BL/LL
RR at recruitment t = end 0.156 BL/LL
RR at recruitment t = x 0.034 TT/BT
RR at recruitment t = x 0.037 TT/BT
RR at recruitment t = x 0.764 BL/LL
RR at recruitment t = end 0.003 BL/LL
RR at recruitment t = x 0.067 TT/BT
RR at recruitment t = end 0.184 TT/BT
RR at recruitment t = x 0.124 TT/BT
RR at recruitment t = end 0.111 TT/BT
RR at recruitment t = x 0.054 TT/BT
RR at recruitment t = end 0.030 TT/BT
RR at recruitment t = x 1.669 BL/LL
RR at recruitment t = end 1.550 BL/LL
RR at recruitment t = x 0.035 BL/LL
RR at recruitment t = end 0.505 BL/LL
RR at recruitment t = x no TT/BT
RR at recruitment t = end 0.088 TT/BT
RR at recruitment t = x 0.148 TT/BT
RR at recruitment t = end 0.061 TT/BT
RR at recruitment t = end 3.099 BL/LL
RR at recruitment t = x 1.848 BL/LL
RR at recruitment t = x 0.228 BL/LL
RR at recruitment t = end nt BL/LL
RR at recruitment t = x 0.363 BL/LL
RR at recruitment t = end 0.113 BL/LL
RR at recruitment t = x 0.286 BL/LL
RR at recruitment t = x 0.217 TT/BT
RR at recruitment t = end 0.062 TT/BT
OD450> 0.2 are considered positive; positive values are indicated in bold; nt = not
tested.
Table 2 (Continued)
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withdraw from the study without consequences for their
treatment. Written informed consent was obtained before enrol-
ment. All patients received treatment according to national
guidelines. Ethical approval for the study protocol was obtained
through the Nepal Health Research Council (NHR #751).
2.3. Recruitment
Newly diagnosed, untreated leprosy patients without clinical
reactions were enrolled. Blood and urine were collected before MDT
(t = 0). Patients who presented reactions within 3 months of the start
of therapy were excluded to avoid proﬁle analyses of patients with
latent reactions. If patients presented with reactions after more than
3 months of MDT, samples were taken before the initiation of anti-
reactional therapy (t = x). Newly diagnosed leprosy patients who
visited clinics with RR were recruited (t = x), but consequently
lacked t = 0 samples. Blood (serum) and urine were collected after
MDT and/or steroid therapy from all patients (t = end). For patientswith RR this was done at least 1 month after the completion of
steroid therapy to avoid assessment of the effect of steroids. All
patients were assessed for the absence of reactions at 3 months after
t = end. For patients showing clinical signs of reactions within
3 months after t = end, this time point was excluded. In the case of a
patient death, or if the patient moved or withdrew from the study
thereby preventing follow-up, their samples were excluded. Urine
and sera were stored at 80 8C.
2.4. Serology
Antibodies against disaccharide-octyl bovine serum albumine
(ND-O-BSA), a synthetic analogue of phenolic glycolipid I (PGL-I),
were determined in the sera, as described previously.19
2.5. Urinary creatinine levels
Assuming that urinary creatinine excretion is constant across
and within individuals, creatinuria was determined as a
normalizer.20 For all urine samples, the levels of creatinine were
determined using the CREA Plus Test according to the manufac-
turer’s protocol (Roche Diagnostics, Indianapolis, IN, USA).
2.6. Metabolomic analysis of urine samples by ultra-performance
liquid chromatography electrospray ionization time-of-ﬂight mass
spectrometry (UPLC-ESI-TOF MS)
Urine samples (10 ml) from the cohorts in Nepal were stored in
15-ml sterile polypropylene tubes (Greiner Bio-one; catalogue
number 188271) and kept frozen until analysis. Urine samples
were prepared for non-targeted analysis of small molecules and
natively occurring urinary peptides. The urinary metabolomics
analysis was performed as described previously.21 Chro-
matographic and mass spectrometry procedures are described
in the Supplementary Material.
2.7. Liquid chromatography mass spectrometry (LC-MS) data analysis
LC-MS data ﬁles were exported as mzXML ﬁles and aligned using
the alignment algorithm msalign2 tool22 developed in-house (http://
www.ms-utils.org/msalign2/); peak picking was performed using
XCMS package (The Scripps Research Institute, La Jolla, CA, USA).14
The data matrix generated was imported into SIMCA-P
13.0 software package (Umetrics, Umea˚, Sweden). The data were
mean-centred and unit variance-scaled prior to statistical analysis.
The validity and the degree of over-ﬁtting of the partial least
square-discriminant analysis (PLS-DA) models were checked using
a 200 permutations test.
The statistical analysis was performed in R version 3.1.3. To
identify metabolites of interest, rational chemical formulae were
generated based on internally calibrated monoisotopic masses
within 10 mDa mass error, using the SmartFormula tool within the
Data Analysis software package (Bruker Daltonics).
3. Results
3.1. An overview of the dataset
An exploratory metabolomics study is a method to obtain an
unbiased view of a research question thereby addressing it beyond
the existing paradigm. The data evaluation typically consists of
several steps, namely evaluation of analytical consistency, an
overview of the main sources of variance, and supervised
modelling following the main lines of the study design. The score
plot of the initial principal component analysis (PCA) model built
on the entire dataset showed that the ﬁrst two principal
O.A. Mayboroda et al. / International Journal of Infectious Diseases 45 (2016) 46–52 49components of the model covered 53% of the variance (Supple-
mentary Material, Figure S1). A tight clustering of the quality
control (QC) samples (a pool of all the samples within a study)
provides an estimate of the fraction of analytical variance within a
dataset. Next, a PCA model was built without QC samples
(11 components explained approximately 60% of variance;
Supplementary Material, Figure S2). However, neither the
differences between the endemic controls and leprosy patients,
nor those between patients with and without leprosy reactions,
inﬂuenced the ﬁrst two components.
3.2. Comparison of urine samples derived from endemic controls and
leprosy patients
The initial PCA model (Supplementary Material, Figure S2)
failed to describe any tendencies in the data associated with the
study design, which is likely due to the fact that the cohort
consisted of a cross-sectional and a longitudinal component
(Supplementary Material, Figure S3). Therefore, the analysis was
restricted to samples obtained at ﬁrst recruitment (t = 0) to
determine whether the urinary metabolic proﬁles reﬂected any
differences between endemic controls and leprosy patients.
Figure 1A shows a PCA model built on this selection of the
samples. A visual inspection of the score plot for the ﬁrst two
components covering 42% of the variance showed no obvious
grouping according to the disease status, although a clear tendency
was present. Thus, a PLS-DA model with disease status as a class
variable was built for the baseline samples. The statistical
parameters of the model (R2X = 0.58, R2Y = 0.99, Q2 = 0.748)
and an additional model diagnostic based on analysis of variance of
the cross-validated residuals (CV-ANOVA) (F = 8.23 and
p = 1.2e08) indicated a valid model (Figure 1B). In contrast,
creatinine levels of all individuals in this study did not provideFigure 1. Urinary metabolic proﬁles can be used to discriminate between endemic contro
baseline (seven components cover 0.58 of variance). (B) Cross-validated score plot of a re
F = 8.23, p = 1.2e08).discriminating potential (Supplementary Material, Figure S5),
thereby indicating that the urinary biomarkers identiﬁed in this study
are disease (state)-speciﬁc. This shows that the urinary metabolic
proﬁles can indeed be useful for discriminating between leprosy
patients and endemic controls. However, it should be taken into
account that other mycobacterial infections may lead to similar
metabolites as identiﬁed in leprosy patients. Therefore future studies
should include the analysis of TB patients from the same region.
3.3. Treatment effect on urinary proﬁles
Taking advantage of the longitudinal sampling, regression
models were built using the urinary samples of patients
developing RR. The ﬁrst model explored the differences between
patients at t = 0 (at least 3 months before the reactions diagnosis)
and at the time of the diagnosis of the reaction, before starting anti-
reactional therapy (t = x) (Figure 2A). The model parameters
(R2X = 0.496, R2Y = 0.995, Q2 = 0.691) indicated a valid model.
However, the CV-ANOVA values were lower than those for the
baseline model (F = 3.55, p = 3.8e03). The next model (Figure 2B)
was built on the urine samples from Nepalese leprosy patients at
diagnosis of reaction before starting anti-reactional therapy (t = x)
and at t = end, at least 1 month after the end of anti-reactional
(steroids) therapy. Model parameters (R2X = 0.363, R2Y = 0.662,
Q2 = 0.114) indicated low predictive power, which was supported
by CV-ANOVA values (F = 1.25, p = 0.3).
3.4. Variable subset selection
One of the advantages of the multivariate regression model is
the possibility of ranking the variables according to their
contribution to the model. This ranking is often presented as a
variable inﬂuence on projection (VIP) value calculated for everyls and leprosy patients. (A) Score plot of a PCA model of urinary metabolomics data at
gression (PLS-DA) model for the same dataset (R2Y = 0.528, R2Y = 0.99, Q2 = 0.748;
A B
Figure 2. Urinary metabolic proﬁles reﬂect the status of the leprosy patients.
(A) Cross-validated score plot of a PLS-DA model built on the samples from all Nepalese leprosy patients in the absence of any clinical signs of reactions and at least 3 months
before the reaction diagnosis (t = 0) and at the time point of the reaction diagnosis and before starting anti-reactional therapy (t = x). (B) Cross-validated score plot of a PLS-DA
model built on the urine samples from Nepalese leprosy patients at the time point of the reaction diagnosis and before starting anti-reactional therapy (t = x) and at t = end at
least 1 month after the end of anti-reactional (steroids) therapy.
Table 3






X836 564.266  0.003 5.1 Most probably a peptide
X937 207.142  0.001 5.2 A few possible ID matches like
ammonium adduct of
homocitrulline were rejected
X484 330.539  0.002 4.1
X405 636.086  0.007 5.2 Triple charged feature, most
probably a peptide
RT, retention time.
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be concluded that two models were statistically signiﬁcant: the
baseline model describing the differences between the endemic
controls and the patients, and the model describing the changes in
the urinary proﬁles of leprosy patients upon the development of a
reaction. Since both models were built on the same matrix of
variables, the degree of overlap between the VIP values was
investigated. A selection of the variables for a comparison was
made using a ‘cut-off’ VIP value of 1.7. The cut-off value was chosen
empirically keeping in mind an imbalance between the number of
observations and the number of variables. A Venn diagram of the
preselected VIP values for both models (Supplementary Material,
Figure S4) showed little overlap between the VIP lists. Therefore, it
can be concluded that the difference in urinary compounds
between the endemic controls and the leprosy patients, as well as
the changes during development of reactions, are explained by a
speciﬁc, barely overlapping set of metabolites.
Nevertheless, a number of practical limitations currently
prevent us from providing the high conﬁdence ID of the
metabolites. First, the limited sample volumes rules out the
possibility of in-depth de novo identiﬁcation of the structures.
Secondly, the available database contains very limited numbers of
documented entries from the endemic areas, since this is based on
reference databases created with samples of European or North
American origin.23 The MS/MS performed on the pooled samples
(endemic controls, leprosy, and the samples at the time of reaction)
helped to resolve structures of some features: a combination of the
accurate mass and retention time provided suggestions for the
others, but there is a large fraction of the features where the
number of potential candidates is just too high to report. Under
these circumstances a table consisting of multiple variables with
only tentative IDs may appear misleading. Thus, the number of
reported variables of the discriminating metabolites was reduced
to an essential minimum, reporting them as unknown ortentatively identiﬁed features (m/z – retention time pair;
Table 3). To this end, p-values were calculated (Mann–Whitney
U-test with Benjamini–Hochberg correction for multiple testing)
for all selected VIP values, for both the baseline (t = 0) and reaction
development models. The variables that passed a commonly
accepted signiﬁcance level of 0.05 were used to build a sequence
of the logistic regression models. The models were built in a
stepwise manner, starting with a single variable and adding/
deleting one variable at a time until the addition of the next
variable failed to improve the model. The models were compared
based on their Akaike information criteria (AIC) and Chi-square
probability. The receiver operating characteristic (ROC) curves for
the optimal models are presented in Figure 3.
4. Discussion
Biomarkers as reliable correlates of disease and the response to
therapy are essential tools for early diagnosis of disease
complications in chronic infections. Generally, the performance


































Figure 3. Receiver operating characteristic (ROC) curve plots for logistic regression models describing discrimination between the endemic controls and leprosy patients (A;
Chi-square (2) = 27.737, p = 1.905225e05) and the differences between t = 0 and t = x (B; Chi-square (2) = 24.367, p = 5.114389e06).
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proﬁle or signature.
The availability of sensitive and speciﬁc biomarkers that aid the
early diagnosis of leprosy reactions as well as monitoring therapy,
would be a strategic advantage enabling health care workers to
identify, treat, and possibly prevent these episodes at an early
stage, thereby reducing nerve damage. With this study, an attempt
was made to extend a conventional area of the search for
biomarkers of leprosy towards urine, aiming at non-invasive
testing. For the ﬁrst time in mycobacterial diseases, it was shown
that the urinary metabolome can be used to discriminate endemic
controls from patients. Moreover, the urinary metabolic signatures
of patients developing RR were clearly different in the absence of
RR before onset compared to those at diagnosis of this reaction. A
simple comparison of the top VIP values from the baseline and
treatment models shows that the differences between leprosy
patients and the endemic controls, as well as changes during
development of the reaction, are associated with different parts of
the urinary metabolome. Although this report does not describe
the ﬁrst metabolomics analysis of leprosy patients, two previous
reports used patient serum and were primarily targeted at testing
an existing paradigm of leprosy pathogenesis (e.g., involvement of
the signalling lipids).24,25 Urine has been used so far either for
monitoring dapsone metabolism,26 or for targeted screening of
Mycobacterium leprae-derived PGL-I.27 In contrast, the present
study had a clear exploratory character and aimed at new
biomarkers for disease (state).
Thus, this ﬁrst demonstration of the discriminative power of
metabolomics analysis for leprosy is an important ﬁnding in the
ﬁeld, particularly since urine represents a more easily accessible
sample than blood. The application of the metabolites identiﬁed
using the approach described in this study in non-invasive ﬁeld-
friendly tests for leprosy would be very useful for monitoring
treatment and for the early diagnosis of reactions. Since several
lateral ﬂow assays for the detection of cytokines/chemokines in
blood samples have already been developed and ﬁeld-tested,28–32
it is envisaged that the translation of this metabolic biomarker
study into ﬁeld-friendly, non-invasive diagnostic tests will also be
feasible.
These data prompt further investigations on urinary metabo-
lites for leprosy and reactions, but also offer possibilities for TB,
particularly in children in whom diagnosis using sputum is
difﬁcult.Moreover, in view of the shared susceptibility genes between
leprosy and other chronic diseases with acute inﬂammatory states,
such as psoriasis33 and Crohn’s disease,34 this leprosy-based
metabolomics approach could be used as a model for other diseases.
An unequivocal identiﬁcation of the metabolites contributing to
speciﬁc signatures will require conﬁrmation in future studies.
Although practical problems, such as the limited availability of
material for conﬁrmatory studies and a bias of the current
metabolomics databases towards material collected in developed
countries, hampered the identiﬁcation of the exact metabolites
based on the current data, the information provided in this study
indicates the presence of different metabolic biomarker proﬁles for
leprosy disease and reactions and offers promise for future studies.
In summary, RRs are a major cause of leprosy-related nerve
impairment and bear similarities to acute inﬂammation-induced
episodes in other infectious diseases. Since there is no laboratory
test for the early diagnosis of these episodes, this longitudinal
study on the occurrence of RR in leprosy patients showed, for the
ﬁrst time, that urinary metabolic proﬁles correlating with an early
onset of RR can be identiﬁed. These metabolic biomarkers are
promising tools for application in rapid, ﬁeld-friendly tests,29
allowing the detection of intra-individual changes during acute
inﬂammatory responses in chronic diseases. Future studies should
be performed to assess their predictive value for the early
diagnosis of these episodes and to contribute to timely treatment
and the reduction/prevention of tissue damage.
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